Medical AI Future: Sustainable Reimbursement Strategies

By HEOR Staff Writer

May 6, 2024

Introduction

Artificial Intelligence (AI) in medicine has the potential to significantly enhance patient care, yet its widespread adoption is very dependent on sustainable reimbursement models. In a recent article, authors examine how fee-for-service (FFS) and value-based care (VBC) can facilitate the scaling of medical AI, and they propose strategies to align stakeholder interests.

The Challenge of Medical AI Reimbursement

Medical AI’s promise to enhance patient outcomes faces a significant obstacle: achieving sustainable reimbursement. Although the U.S. healthcare system offers a blueprint for this process, the path to reimbursement is filled with multiple complexities, necessitating the collaboration of diverse stakeholders.

Fee-for-Service: A Traditional Approach

FFS remains a prevalent model where medical AI services are billed similarly to other medical interventions. While this model offers transparency and can provide financial sustainability, it is not without risks, such as potential over utilisation and exacerbation of health disparities.

The Shift to Value-Based Care

VBC is reshaping the reimbursement landscape by focusing on patient outcomes and efficiency. This model accounts for a substantial portion of U.S. healthcare spending and offers fewer regulatory constraints. However, the real-world impact of VBC on cost and quality of care remains mixed.

Emerging Models and Real-World Cases

New reimbursement models are emerging, such as revenue-sharing approaches akin to the Medicare Part B drug payment system. Real-world cases, like autonomous AI for diabetic eye examinations, demonstrate how FFS and VBC can be effectively leveraged for reimbursement.

Accelerating Adoption Through Strategic Reimbursement

To expedite the adoption of medical AI, creators must navigate the reimbursement landscape effectively. This may involve pursuing FFS pathways, such as establishing a Current Procedural Terminology (CPT) code, or integrating into existing VBC frameworks like Merit-Based Incentive Payment Systems/ Healthcare Effectiveness Data and Information Set (MIPS/HEDIS).

Conclusion

The journey towards sustainable reimbursement for medical AI is complex, yet essential for its successful integration into healthcare. By understanding and utilising current FFS and VBC models, stakeholders can ensure that medical AI reaches its full potential in improving patient outcomes.

Reference url

Recent Posts

CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
Ravulizumab aHUS Reimbursement Reassessment: Navigating New Evidence and Treatment Impact

By HEOR Staff Writer

September 15, 2025

Zorginstituut Nederland is reassessing ravulizumab aHUS reimbursement for treating atypical hemolytic uremic syndrome (aHUS) - a rare immune system disorder. The drug was previously rejected in 2021 due to insufficient scientific evidence. The medication is administered via infusion and targets p...